"If the company was so confident about safety features of its product, it should have come forward and requested us to go for a re-test of the samples or it could have offered other samples for a fresh examination," FDA counsel Darius Khambata submitted before justices V M Kanade and B P Colabawala.
The court was hearing a petition filed by Nestle against FSSAI's June 5 order banning nine variants of Maggi, and Maharashtra government's order prohibiting their sale.
FDA selected at random 20 samples of Maggi for the test and five of them tested positive for containing lead beyond permissible limit. This was enough for FDA to issue notice to stop production and sale of all the 9 variants of Maggi, Khambata said.
If the company suspected that the FDA reports were not correct then it could have made a grievance before the food regulator to send the samples to an accredited lab in Pune or Nagpur, instead of rushing to the high court to challenge the ban imposed on production and sale of the product, he argued.
"Instead, Nestle chose to send samples to labs in London, New York and Paris and placed 2700 test reports before us (FDA) to show that lead content was proper," he said.
Justifying the ban, FDA counsel argued that after tests when FDA found lead content in Maggi to be beyond permissible limit, it issued an order banning the product.
Moreover, FDA had sent lab test reports to Nestle but the company has not included these in the petition, thereby suppressing this fact from the high court, he said.
Both FSSAI and FDA have claimed that they had issued notices to Nestle India keeping in mind the health hazards the product may have had due to the high lead content.
Nestle has argued that a particular batch may have contained lead beyond permissible limit but the blanket ban was "unfair and illegal".
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)